journal article·2023-01-16Open access

A Review on Phyto-Therapeutic Approaches in Alzheimer’s Disease

Mehtap Sahiner, Aynur Sanem Yilmaz, Buket Gungor, Nurettin Sahiner

Abstract

Neurodegenerative diseases occur due to progressive and sometimes irreversible loss of function and death of nerve cells. A great deal of effort is being made to understand the pathogenesis of neurodegenerative diseases. In particular, the prevalence of Alzheimer’s disease (AD) is quite high, and only symptomatic therapy is available due to the absence of radical treatment. The aim of this review is to try to elucidate the general pathogenesis of AD, to provide information about the limit points of symptomatic treatment approaches, and to emphasize the potential neurologic effects of phytocompounds as new tools as therapeutic agents for disease prevention, retardation, and therapy. This survey also covers the notable properties of herbal compounds such as their effects on the inhibition of an enzyme called acetylcholinesterase, which has significant value in the treatment of AD. It has been proven that phytopharmaceuticals have long-term effects that could protect nervous system health, eliminate inflammatory responses, improve cognitive damage, provide anti-aging effects in the natural aging process, and alleviate dementia sequelae. Herbal-based therapeutic agents can afford many advantages and can be used as potentially as new-generation therapeutics or complementary agents with high compliance, fewer adverse effects, and lower cost in comparison to the traditional pharmaceutical agents in the fight against AD.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Cholinesterase and Neurodegenerative Diseases · Medicinal Plants and Neuroprotection · Alzheimer's disease research and treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Bioengineering, Faculty of Engineering, Canakkale Onsekiz Mart University, Terzioglu Campus, Canakkale 17100, Turkey

Department of Chemistry, Canakkale Onsekiz Mart University, Terizoglu Campus, Canakkale 17100, Turkey

Department of Pharmacology, School of Medicine, Canakkale Onsekiz Mart University, Terzioglu Campus, Canakkale 17100, Turkey

Nanoscience and Technology Research and Application Center (NANORAC), Canakkale Onsekiz Mart University, Terzioglu Campus, Canakkale 17100, Turkey

Department of Ophthalmology, Morsani College of Medicine, University of South Florida, 12901 Bruce B. Downs Blv., MDC 21, Tampa, FL 33620, USA

Department of Chemical, Biological, and Materials Engineering, University of South Florida, Tampa, FL 33620, USA

References (100+)

Show source-provided references
1. Amyloid β Pathology in Alzheimer’s Disease and Schizophrenia10.1176/appi.ajp.160.5.867 ↗
2. Neuropsychiatric symptoms in Alzheimer’s disease10.1016/j.jalz.2011.05.2410 ↗
3. Alzheimer’s disease and vascular dementia in developing countries: Prevalence, management, and risk factors10.1016/S1474-4422(08)70169-8 ↗
4. The effect of physical exercise on cerebral blood flow in Alzheimer’s disease10.1016/j.nicl.2018.09.003 ↗
5. The clinical practice of risk reduction for Alzheimer’s disease: A precision medicine approach10.1016/j.jalz.2018.08.004 ↗
6. Breijyeh, Z., and Karaman, R. (2020). Comprehensive Review on Alzheimer’s Disease: Causes and Treatment. Molecules, 25.10.3390/molecules25245789 ↗
7. Biomarkers for Alzheimer’s Disease Diagnosis10.2174/1567205014666170203125942 ↗
8. Mini-Mental State Examination (MMSE) for the detection of Alzheimer’s disease and other dementias in people with mild cognitive impairment (MCI)
9. Memantine in Moderate-to-Severe Alzheimer’s Disease10.1056/NEJMoa013128 ↗
10. Spreading of Amyloid, Tau, and Microvascular Pathology in Alzheimer’s Disease: Findings from Neuropathological and Neuroimaging Studies10.3233/JAD-141461 ↗
11. Pathology and Pathways of Alzheimer’s Disease with an Update on New Developments in Treatment10.1046/j.1532-5415.5157.x ↗
12. Age-specific and Sex-specific Prevalence and Incidence of Mild Cognitive Impairment, Dementia, and Alzheimer Dementia in Blacks and Whites10.1097/WAD.0b013e31823dbcfc ↗
13. Intranasal Piperine-Loaded Chitosan Nanoparticles as Brain-Targeted Therapy in Alzheimer’s Disease: Optimization, Biological Efficacy, and Potential Toxicity10.1002/jps.24557 ↗
14. Larsson, S., and Orsini, N. (2018). Coffee Consumption and Risk of Dementia and Alzheimer’s Disease: A Dose-Response Meta-Analysis of Prospective Studies. Nutrients, 10.10.3390/nu10101501 ↗
15. Prince, M., Albanese, E., Guerchet, M., and Prina, M. (2014). World Alzheimer Report 2014 Dementia and Risk Reduction, Alzheimer’s Disease International.
16. Global prevalence of dementia: A Delphi consensus study10.1016/S0140-6736(05)67889-0 ↗
17. Epidemiology of Alzheimer Disease10.1101/cshperspect.a006239 ↗
18. Prince, M., Wimo, A., Guerchet, M., Ali, G., Wu, Y., and Prina, M. (2015). World Alzheimer Report 2015—The Global Impact of Dementia: An Analysis of Prevalence, Incidence, Cost and Trends, Alzheimer’s Disease International.
19. The Relationships Between Age, Sex, and the Incidence of Dementia and Alzheimer Disease10.1001/archpsyc.55.9.809 ↗
20. Gender and Age Differences and the Trend in the Incidence and Prevalence of Dementia and Alzheimer’s Disease in Taiwan: A 7-Year National Population-Based Study10.1155/2019/5378540 ↗
21. Prevalencia e incidencia de la enfermedad de Alzheimer en Europa: Metaanálisis10.1016/j.nrl.2016.02.016 ↗
22. The Prevalence and Incidence of Dementia Due to Alzheimer’s Disease: A Systematic Review and Meta-Analysis10.1017/cjn.2016.36 ↗
23. Incidence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group
24. Gender differences in the incidence of AD and vascular dementia: The EURODEM Studies10.1212/WNL.53.9.1992 ↗
25. Alzheimer’s disease10.1111/ene.13439 ↗
26. Alzheimer’s disease10.1016/S0140-6736(06)69113-7 ↗
27. Characterization of Dementia and Alzheimer’s Disease in an Older Population: Updated Incidence and Life Expectancy with and without Dementia10.2105/AJPH.2014.301935 ↗
28. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: An analysis for the Global Burden of Disease Study 201910.1016/S2468-2667(21)00249-8 ↗
29. (2021). 2021 Alzheimer’s disease facts and figures. Alzheimer’s Dement., 17, 327–406.10.1002/alz.12328 ↗
30. Trends in the incidence and prevalence of Alzheimer’s disease, dementia, and cognitive impairment in the United States10.1016/j.jalz.2010.11.002 ↗
31. Alzheimer’s disease: Pathogenesis, diagnostics, and therapeutics10.2147/IJN.S200490 ↗
32. The existence of primary age-related tauopathy suggests that not all the cases with early braak stages of neurofibrillary pathology are Alzheimer’s disease10.3233/JAD-150435 ↗
33. Apolipoprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease10.1073/pnas.90.5.1977 ↗
34. Katzman, R., and Kawas, C. (1994). The epidemiology of dementia and Alzheimer disease. Alzheimer Disease, UC Irvine.
35. Neurodegeneration in Alzheimer Disease: Role of Amyloid Precursor Protein and Presenilin 1 Intracellular Signaling10.1155/2012/187297 ↗
36. Assembly, Maturation, and Trafficking of the γ-Secretase Complex in Alzheimers Disease10.2174/156720508783954695 ↗
37. A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia10.1111/j.1471-4159.2009.06042.x ↗
38. The Molecular Pathology of Alzheimer’s Disease10.1016/j.nic.2011.11.003 ↗
39. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: A systematic review and meta-analysis10.1016/S1474-4422(09)70236-4 ↗
40. Hippocampal and cortical atrophy predict dementia in subcortical ischemic vascular disease10.1212/WNL.55.11.1626 ↗
41. Coronary Artery Disease, Hypertension, ApoE, and Cholesterol: A Link to Alzheimer’s Disease?10.1111/j.1749-6632.1997.tb48466.x ↗
42. Midlife blood pressure and dementia: The Honolulu–Asia aging study☆10.1016/S0197-4580(00)00096-8 ↗
43. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: The HAAS☆
44. The significance of environmental factors in the etiology of Alzheimer’s disease10.3233/JAD-2002-4308 ↗
45. Expression of human apolipoprotein E reduces amyloid-β deposition in a mouse model of Alzheimer’s disease10.1172/JCI6179 ↗
46. Transport of Insulin Across the Blood-Brain Barrier: Saturability at Euglycemic Doses of Insulin10.1016/S0196-9781(97)00231-3 ↗
47. The Origins of Alzheimer Disease10.1001/jama.283.12.1615 ↗
48. Glycogen Synthase Kinase 3 Inhibitors in the Next Horizon for Alzheimer’s Disease Treatment10.4061/2011/280502 ↗
49. APOE-ε4 predicts dementia but not other psychiatric disorders after traumatic brain injury10.1212/01.WNL.0000134603.57107.2F ↗
50. Amyloid-β Peptides and Tau Protein as Biomarkers in Cerebrospinal and Interstitial Fluid Following Traumatic Brain Injury: A Review of Experimental and Clinical Studies10.3389/fneur.2013.00079 ↗
51. Brain injury, neuroinflammation and Alzheimer’s disease10.3389/fnagi.2013.00026 ↗
52. Meta-Analysis of Alzheimer’s Disease Risk with Obesity, Diabetes, and Related Disorders10.1016/j.biopsych.2009.02.013 ↗
53. Alzheimer Disease and Oxidative Stress
54. Drug treatments in Alzheimer’s disease10.7861/clinmedicine.16-3-247 ↗
55. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease10.1016/j.jalz.2018.02.018 ↗
56. Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer‘s disease10.1093/brain/awu213 ↗
57. Molecular mechanisms of neurodegeneration in Alzheimer’s disease10.1093/hmg/ddq160 ↗
58. Fluid and PET biomarkers for amyloid pathology in Alzheimer’s disease10.1016/j.mcn.2018.12.004 ↗
59. Seeding “one-dimensional crystallization” of amyloid: A pathogenic mechanism in Alzheimer’s disease and scrapie?10.1016/0092-8674(93)90635-4 ↗
60. Regional Distribution of Neuritic Plaques in the Nondemented Elderly and Subjects with Very Mild Alzheimer Disease10.1001/archneur.55.9.1185 ↗
61. Alzheimer’s and Parkinson’s diseases: The prion concept in relation to assembled Aβ, tau, and α-synuclein10.1126/science.1255555 ↗
62. The Neurotrophins and Their Role in Alzheimers Disease10.2174/157015911798376190 ↗
63. Immunological aspects of microglia: Relevance to Alzheimer’s disease10.1016/S0197-0186(01)00045-6 ↗
64. Apoptotic mechanisms in Alzheimer neurofibrillary degeneration: Cause or effect?10.1172/JCI22317 ↗
65. Neurofibrillary Tangles Mediate the Association of Amyloid Load with Clinical Alzheimer Disease and Level of Cognitive Function10.1001/archneur.61.3.378 ↗
66. Neuropathological stageing of Alzheimer-related changes10.1007/BF00308809 ↗
67. Clinical and Biomarker Changes in Dominantly Inherited Alzheimer’s Disease10.1056/NEJMoa1202753 ↗
68. Associations Between Biomarkers and Age in the Presenilin 1 E280A Autosomal Dominant Alzheimer Disease Kindred10.1001/jamaneurol.2014.3314 ↗
69. Bayesian hidden Markov models for delineating the pathology of Alzheimer’s disease10.1177/0962280217748675 ↗
70. Using Positron Emission Tomography and Florbetapir F 18 to Image Cortical Amyloid in Patients with Mild Cognitive Impairment or Dementia Due to Alzheimer Disease10.1001/archneurol.2011.150 ↗
71. Imaging the Alzheimer Brain10.3233/JAD-2011-0073 ↗
72. Tacrine therapy for the dementia of Alzheimer’s disease
73. Versatile Fluorescent Carbon Dots from Citric Acid and Cysteine with Antimicrobial, Anti-biofilm, Antioxidant, and AChE Enzyme Inhibition Capabilities10.1007/s10895-021-02798-x ↗
74. Cholinesterase Inhibitors for the Treatment of Alzheimer’s Disease: Getting on and staying on10.1016/S0011-393X(03)00059-6 ↗
75. Galantamine in AD10.1212/WNL.54.12.2261 ↗
76. Birks, J.S. (2006). Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database of Systematic Reviews, John Wiley & Sons, Ltd.10.1002/14651858.CD005593 ↗
77. Effects of nicotine on APP secretion and Aβ- or CT105-induced toxicity10.1016/S0006-3223(00)01124-0 ↗
78. Long-term tacrine (Cognex) treatment10.1212/WNL.47.1.166 ↗
79. Suner, S.S., Sahiner, M., Ayyala, R.S., Bhethanabotla, V.R., and Sahiner, N. (2020). Nitrogen-Doped Arginine Carbon Dots and Its Metal Nanoparticle Composites as Antibacterial Agent. C—J. Carbon Res., 6.10.3390/c6030058 ↗
80. EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer’s disease10.1111/ene.12707 ↗
81. Memantine in patients with Alzheimer’s disease receiving donepezil: New analyses of efficacy and safety for combination therapy10.1186/alzrt160 ↗
82. Cerebral Hemorrhage after Passive Anti-Abeta Immunotherapy10.1126/science.1078259 ↗
83. Antidepressants for treating depression in dementia
84. Statins and the risk of dementia10.1016/S0140-6736(00)03155-X ↗
85. Simvastatin strongly reduces levels of Alzheimer’s disease -amyloid peptides A 42 and A 40 in vitro and in vivo10.1073/pnas.081620098 ↗
86. Patterns of Brain Activation in People at Risk for Alzheimer’s Disease10.1056/NEJM200008173430701 ↗
87. Dietary Intake of Antioxidant Nutrients and the Risk of Incident Alzheimer Disease in a Biracial Community Study10.1001/jama.287.24.3230 ↗
88. Folic Acid Deficiency and Homocysteine Impair DNA Repair in Hippocampal Neurons and Sensitize Them to Amyloid Toxicity in Experimental Models of Alzheimer’s Disease10.1523/JNEUROSCI.22-05-01752.2002 ↗
89. Use of Magnetization Transfer Contrast MRI to Detect Early Molecular Pathology in Alzheimer’s Disease10.1002/mrm.24665 ↗
90. Phytopharmaceutical treatment of anxiety, depression, and dementia in the elderly: Evidence from randomized, controlled clinical trials10.1007/s10354-015-0360-y ↗
91. Design, synthesis and evaluation of a novel metal chelator as multifunctional agents for the treatment of Alzheimer’s disease10.1016/j.bioorg.2019.03.064 ↗
92. Development of grape polyphenols as multi-targeting strategies for Alzheimer’s disease10.1016/j.neuint.2021.105046 ↗
93. Rosmarinic acid suppresses Alzheimer’s disease development by reducing amyloid β aggregation by increasing monoamine secretion10.1038/s41598-019-45168-1 ↗
94. Enhancement of biocompatibility and carbohydrate absorption control potential of rosmarinic acid through crosslinking into microparticles10.1016/j.ijbiomac.2019.07.032 ↗
95. Phytochemical profiling of Blumea laciniata (Roxb.) DC. and its phytopharmaceutical potential against diabetic, obesity, and Alzheimer’s10.1016/j.biopha.2021.111859 ↗
96. Current understanding of metal ions in the pathogenesis of Alzheimer’s disease10.1186/s40035-020-00189-z ↗
97. Sahiner, N. (2021). Self-Crosslinked Ellipsoidal Poly(Tannic Acid) Particles for Bio-Medical Applications. Molecules, 26.10.3390/molecules26092429 ↗
98. Degradable poly(catechin) nanoparticles as a versatile therapeutic agent10.1080/00914037.2021.1941957 ↗
99. Benchikha, N., Messaoudi, M., Larkem, I., Ouakouak, H., Rebiai, A., Boubekeur, S., Ferhat, M.A., Benarfa, A., Begaa, S., and Benmohamed, M. (2022). Evaluation of Possible Antioxidant, Anti-Hyperglycaemic, Anti-Alzheimer and Anti-Inflammatory Effects of Teucrium polium Aerial Parts (Lamiaceae). Life, 12.10.3390/life12101579 ↗
100. Messaoudi, M., Rebiai, A., Sawicka, B., Atanassova, M., Ouakouak, H., Larkem, I., Egbuna, C., Awuchi, C.G., Boubekeur, S., and Ferhat, M.A. (2021). Effect of Extraction Methods on Polyphenols, Flavonoids, Mineral Elements, and Biological Activities of Essential Oil and Extracts of Mentha pulegium L.. Molecules, 27.10.3390/molecules27010011 ↗